反応式
Brc1cccnc1.CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2>CC(C)(C)[O-].Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1cccnc1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 85 °C
実験手順
TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (0.055 g, 0.06 mmol) and rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.075 g, 0.12 mmol) were mixed together and evacuated and purged with nitrogen 3 times. toluene (29.7 ml) was added and the resulting mixture heated to 90°C for 10 minutes then cooled to room temperature. In a second reaction vessel was mixed sodium tert-butoxide (0.465 g, 4.84 mmol), 3-bromopyridine (0.321 ml, 3.33 mmol) and (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (0.601 g, 3.03 mmol) and toluene (29.7 ml). The mixture was evacuated and purged with nitrogen 3 times. The solution of catalyst was added to the reaction mixture and the resulting mixture was heated at 85 °C for 64 hours. The reaction mixture was cooled to RT and filtered through celite and concentrated to give an orange solid. The crude product was purified by flash silica chromatography, elution gradient 30 to 50% EtOAc in heptane. Then 100% MeOH. Pure fractions were evaporated to dryness to afford (1S,4S)-tert-butyl 5-(pyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (0.823 g, 99 %) as a pale yellow dry film.
出典と根拠
- ORDレコード
- ord-218b24f2d22444388b751f136d342319
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…